Some of iHub’s finest bashers took the opportunity to spin the news from yesterday about Sean Spicer saying he expects states to see ‘greater enforcement’ of marijuana laws. Why wouldn’t they? Their strategy is to be dishonest and scare people into selling, I assume.
If the bashers have you worried about today or the future of marijuana stocks in general, you first must know that the actual comments of from the Press Secretary had nothing to do with the medical marijuana industry. Watch and listen to his comments for yourself in this video.
Spicer, taking questions from reporters at the daily briefing, differentiated between the administration’s positions on medical marijuana and recreational marijuana.President Donald Trump “understands the pain and suffering that many people go through who are facing especially terminal diseases, and the comfort that some of these drugs, including medical marijuana, can bring to them,” he said, also noting previous action by Congress not to fund the Justice Department “go[ing] after those folks.”
As for “recreational marijuana, that’s a very, very different subject,” Spicer said.
Anyone with an even partially open mind should easily be able to determine that if any marijuana stocks are in trouble — it’s the ones who serve the recreational sector. If there is a sell off in the recreational sector, that should only mean good things for the medical sector. After all, the marijuana sector/industry is hot and the medical sector became more of a sure bet to skeptics.
Obviously this site has been very pro-OWCP since October (and again, we welcome contributor writers to do DD Blogs about virtually any legit, low float stock), so let’s just talk highlights…
InsiderFinancial.com had a nice article earlier this week that ended with, “OWCP is one of the most exciting plays for cannabis investors in the entire space right now. The company owns its IP and there’s significant value in the IP alone. As the company makes it way through the approval and commercialization process, its value will increase exponentially. With an experienced management team and a strong advisory board, OWCP has positioned itself to achieve its goals.”
It’s a pretty solid article overall. They highlight a lot of the pluses of investing in a promising company (OWCP). They compared it to GWPH, which they note has a Market Cap of $3.27 billion.
Here are some of the other highlights from the article:
- The advantage OWCP has doing its research in Israel.
- OWCP signed 3 research collaboration and license agreements with ‘the most comprehensive medical center in the Middle East’
- Dr. Yehuda Baruch and how he was the head of the ‘Israeli Medical Cannabis Unit’ under the Minister of Health for over 10 years.
- The Psoriasis cream being in it’s final round of efficacy testing before it hits shelves.
- OWCP expects to have product commercially available by end of Quarter 1 with a sales push starting in Quarter 2.
- Considerable upside with the Multiple Myeloma clinical trial
- Sublingual Tablet for a “measurable and quantifiable method of dosing patients”
- Next big update from company expected at Wall Street Conference
So, once again, I remind everyone — the exciting stuff is coming in March, April, and beyond. That’s what we’ve been saying all along. Who cares about the daily ups and downs in February. Sure, the run up to $3.23 on Tuesday was cool and exciting. But, the really stellar run should start up after March 1st.
Maybe now that we saw OWCP run to $3.23 from $0.915 this week, more will see the potential OWCP has in the short term when the study results are announced and the products hit the shelves. The guys calling for $10 – $20 by summer don’t seem so crazy anymore, I bet.
I personally predict Friday (February 24th, 2017) to be pretty good for OWCP. Unless, of course, some people still “don’t get it” and got scared by the Trump administration comments — even though, if anything, they were positive for the medical marijuana sector.